Skip to main content
Skip to main content

Fibroblast Growth Factor (FGF) 1 with Mutation in the Heparin Binding Domain and Methods of Use to Reduce Blood Glucose

Tech ID:
Principal Investigator:
Michael Blaber
Licensing Manager:

Type 2 diabietes and obesity are leading causes of mortality and are associated with the Western lifestyle, which is characterized by excessive nutritional intake and lack of exercise.

The present technology provides mutated FGF1 proteins and methods of their use to reduce blood glucose and/or to treat a metabolic disease.